Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly executive Diogo Rau reported routine equity compensation activity. On February 1, 2026, 3,752 restricted stock units converted into the same number of Eli Lilly common shares at an exercise price of $0, increasing his directly held stock.
On the same day, 1,673.538 shares of common stock were withheld at a price of $1,037.15 per share, a transaction coded “F,” which typically reflects shares retained to cover taxes on vested awards. After these transactions, Rau directly owned 21,797.37 Eli Lilly common shares.
Eli Lilly executive Patrik Jonsson, EVP & President, LLY International, reported equity transactions in company stock on February 1, 2026. He exercised 3,930 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.
To cover taxes from this vesting, 1,752.071 shares of common stock were withheld or disposed of at $1,037.15 per share under transaction code "F." After these transactions, Jonsson directly owned 55,828.568 shares of Eli Lilly common stock and indirectly held 608.95 shares through a 401(k) plan.
Eli Lilly and Company executive Edgardo Hernandez reported equity transactions involving company stock. On February 1, 2026, 3,572 restricted stock units converted into the same number of Eli Lilly common shares at $0 exercise price. On the same date, 1,591.452 common shares were disposed of at $1,037.15 per share.
After these transactions, Hernandez directly held 41,711.983 Eli Lilly common shares and indirectly held 871.94 shares through a 401(k) plan. Each restricted stock unit represents a contingent right to receive one Eli Lilly common share.
Eli Lilly & Co executive Anat Hakim reported routine equity transactions involving restricted stock units and common shares. On 02/01/2026, she converted 6,700 restricted stock units into Eli Lilly common stock at an exercise price of $0.
On the same date, 2,953.395 shares of common stock were withheld at a price of $1,037.15 in a transaction coded "F," typically used for tax withholding, leaving 14,709.105 common shares held directly. Additional indirect holdings are 15,700 common shares held by the Anat Hakim SLAT and 16,875 common shares held by her spouse. She disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.
Eli Lilly executive Eric Dozier, EVP and Chief People Officer, reported several equity transactions dated February 1, 2026. A block of 2,858 restricted stock units converted into the same number of Eli Lilly common shares at $0 per share, increasing his direct holdings. On the same date, a disposition coded “F” covered 1,272.992 common shares at $1,037.15 per share, leaving Dozier with 11,423.918 common shares held directly. He also reports an additional 376.93 common shares held indirectly through a 401(k) account.
Lilly Endowment, Inc., an Indiana not‑for‑profit private foundation, reported its ownership of 92,190,516 shares of Eli Lilly and Company common stock as of December 31, 2025. This stake represents 9.8% of Eli Lilly’s outstanding common stock, based on 945,383,757 shares outstanding as of October 27, 2025, as referenced from Eli Lilly’s Form 10‑Q for the period ended September 30, 2025.
The endowment has sole voting power and sole dispositive power over all 92,190,516 shares and reports no shared voting or shared dispositive power. None of these shares are reported as being beneficially owned through rights to acquire additional shares; they reflect existing common shares held by the endowment.
Eli Lilly and Company director Gabrielle Sulzberger reported a small acquisition of company stock as part of board compensation. On January 20, 2026, she acquired 4.762 shares of Eli Lilly common stock at a price of $1,041.29 per share, bringing her directly held beneficial ownership to 2,961.436 shares.
According to the filing, these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan. They are credited as stock units and are scheduled to be settled in actual shares of common stock after her separation from service as a director. The transaction reflects routine director compensation rather than an open-market purchase or sale.
Eli Lilly and Company director Juan R. Luciano reported an acquisition of company common stock through the deferral of board compensation. On January 20, 2026, he acquired 15.286 shares of Eli Lilly common stock at a price of $1,041.29 per share, recorded as an "A" transaction. After this transaction, he beneficially owned 16,756.656 shares of Eli Lilly common stock in direct ownership.
According to the disclosure, Mr. Luciano elected to defer his cash compensation into stock units under the Lilly Directors' Deferral Plan. These deferred stock units will be settled in shares of common stock after he separates from service as a director, meaning the award is part of his director compensation structure rather than an open-market purchase.
Eli Lilly & Co. director J. Erik Fyrwald reported an acquisition of company common stock through a compensation deferral arrangement. On January 20, 2026, he acquired 9.523 shares of Eli Lilly common stock at $1,041.29 per share, increasing his directly held beneficial ownership to 75,110.75 shares.
According to the disclosure, these shares were not received as immediate cash pay but were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan. They will be settled in shares of common stock after Fyrwald separates from service as a director, reflecting standard equity-based director compensation rather than an open-market trade.
Eli Lilly & Co. director Ralph Alvarez reported acquiring 11.924 shares of Eli Lilly common stock on January 20, 2026. According to the filing, this amount represents fees that he elected to defer as stock units under the Lilly Directors' Deferral Plan, instead of taking cash, and these units will be settled in Eli Lilly common shares after he leaves board service.
Following this transaction, Alvarez directly beneficially owned 55,479.642 shares of Eli Lilly common stock. The filing also reports an additional 758 shares held indirectly through a trust, for which he disclaims beneficial ownership except to the extent of his economic interest.